StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Increased Pricing on Jan 1- Piper Jaffray
January 2, 2020 7:04 AM
Piper Jaffray analyst Christopher Raymond reiterated a Neutral rating and $305.00 price target on Biogen (NASDAQ: BIIB) after Wolters Kluwer ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments